Summary | |
---|---|
Symbol | APLP1 |
Name | amyloid beta (A4) precursor-like protein 1 |
Aliases | APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1 |
Chromosomal Location | 19q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: C30: Cytoplasm. Note=C-terminally processed in the Golgi complex. |
Domain |
PF10515 beta-amyloid precursor protein C-terminus PF12924 Copper-binding of amyloid precursor PF12925 E2 domain of amyloid precursor protein PF02177 Amyloid A4 N-terminal heparin-binding |
Function |
May play a role in postsynaptic function. The C-terminal gamma-secretase processed fragment, ALID1, activates transcription activation through APBB1 (Fe65) binding (By similarity). Couples to JIP signal transduction through C-terminal binding. May interact with cellular G-protein signaling pathways. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I. ; FUNCTION: The gamma-CTF peptide, C30, is a potent enhancer of neuronal apoptosis. |
Biological Process |
GO:0006140 regulation of nucleotide metabolic process GO:0006164 purine nucleotide biosynthetic process GO:0006171 cAMP biosynthetic process GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007193 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0009150 purine ribonucleotide metabolic process GO:0009152 purine ribonucleotide biosynthetic process GO:0009165 nucleotide biosynthetic process GO:0009187 cyclic nucleotide metabolic process GO:0009190 cyclic nucleotide biosynthetic process GO:0009260 ribonucleotide biosynthetic process GO:0030799 regulation of cyclic nucleotide metabolic process GO:0030800 negative regulation of cyclic nucleotide metabolic process GO:0030802 regulation of cyclic nucleotide biosynthetic process GO:0030803 negative regulation of cyclic nucleotide biosynthetic process GO:0030808 regulation of nucleotide biosynthetic process GO:0030809 negative regulation of nucleotide biosynthetic process GO:0030814 regulation of cAMP metabolic process GO:0030815 negative regulation of cAMP metabolic process GO:0030817 regulation of cAMP biosynthetic process GO:0030818 negative regulation of cAMP biosynthetic process GO:0045980 negative regulation of nucleotide metabolic process GO:0046058 cAMP metabolic process GO:0046390 ribose phosphate biosynthetic process GO:0052652 cyclic purine nucleotide metabolic process GO:0071407 cellular response to organic cyclic compound GO:0071417 cellular response to organonitrogen compound GO:0071867 response to monoamine GO:0071868 cellular response to monoamine stimulus GO:0071869 response to catecholamine GO:0071870 cellular response to catecholamine stimulus GO:0071873 response to norepinephrine GO:0071874 cellular response to norepinephrine stimulus GO:0072522 purine-containing compound biosynthetic process GO:1900371 regulation of purine nucleotide biosynthetic process GO:1900372 negative regulation of purine nucleotide biosynthetic process GO:1900542 regulation of purine nucleotide metabolic process GO:1900543 negative regulation of purine nucleotide metabolic process GO:1901293 nucleoside phosphate biosynthetic process |
Molecular Function |
GO:0001664 G-protein coupled receptor binding GO:0005539 glycosaminoglycan binding GO:0008201 heparin binding GO:0031690 adrenergic receptor binding GO:0031694 alpha-2A adrenergic receptor binding GO:0031695 alpha-2B adrenergic receptor binding GO:0031696 alpha-2C adrenergic receptor binding GO:1901681 sulfur compound binding |
Cellular Component |
GO:0005578 proteinaceous extracellular matrix GO:0005604 basement membrane GO:0044420 extracellular matrix component |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | APLP1 |
Name | amyloid beta (A4) precursor-like protein 1 |
Aliases | APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1 |
Chromosomal Location | 19q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between APLP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | APLP1 |
Name | amyloid beta (A4) precursor-like protein 1 |
Aliases | APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1 |
Chromosomal Location | 19q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of APLP1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | APLP1 |
Name | amyloid beta (A4) precursor-like protein 1 |
Aliases | APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1 |
Chromosomal Location | 19q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of APLP1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of APLP1 in various data sets.
|
Summary | |
---|---|
Symbol | APLP1 |
Name | amyloid beta (A4) precursor-like protein 1 |
Aliases | APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1 |
Chromosomal Location | 19q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of APLP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | APLP1 |
Name | amyloid beta (A4) precursor-like protein 1 |
Aliases | APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1 |
Chromosomal Location | 19q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of APLP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by APLP1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | APLP1 |
Name | amyloid beta (A4) precursor-like protein 1 |
Aliases | APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1 |
Chromosomal Location | 19q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of APLP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | APLP1 |
Name | amyloid beta (A4) precursor-like protein 1 |
Aliases | APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1 |
Chromosomal Location | 19q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of APLP1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | APLP1 |
Name | amyloid beta (A4) precursor-like protein 1 |
Aliases | APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1 |
Chromosomal Location | 19q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between APLP1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | APLP1 |
Name | amyloid beta (A4) precursor-like protein 1 |
Aliases | APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1 |
Chromosomal Location | 19q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting APLP1 collected from DrugBank database. |
Details on drugs targeting APLP1.
|